DB05178ExperimentalSmall molecule
DL6001 is developed by DanioLabs using proprietary zebrafish technology to treat Parkinson’s disease symptoms including sialorrhoea and hyperhidrosis.
- Primary indication
- Investigated for use/treatment in parkinson's disease.Curator reviewed
- Code names
- DLO6001
Which companies are running trials of DLO6001, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account